Last €245.85 EUR
Change Today -5.52 / -2.19%
Volume 1.1K
IDP On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 11:16 AM 08/1/14 All times are local (Market data is delayed by at least 15 minutes).

biogen idec inc (IDP) Snapshot

Open
€248.98
Previous Close
€251.37
Day High
€251.05
Day Low
€238.85
52 Week High
07/30/14 - €259.96
52 Week Low
08/20/13 - €152.65
Market Cap
58.1B
Average Volume 10 Days
1.1K
EPS TTM
--
Shares Outstanding
236.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BIOGEN IDEC INC (IDP)

biogen idec inc (IDP) Details

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of multiple sclerosis (MS), neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. It provides AVONEX to treat relapsing MS; TYSABRI to treat relapsing forms of MS and Crohn’s disease; RITUXAN for treating relapsed or refractory, follicular, CD20-positive, and B-cell Non-Hodgkin’s lymphoma (NHL); FUMADERM to treat severe plaque psoriasis in adult patients; FAMPYRA, an oral compound for the improvement of walking in adult patients with MS; TECFIDERA for the treatment of MS; and GAZYVA, an injection for intravenous infusion that treats an untreated chronic lymphocytic leukemia. The company’s products that completed Phase III clinical trials comprise ELOCTATE and ALPROLIX, an inherited disorder that inhibits blood coagulations; and Peginterferon beta-1a to prolong the effects and reduce the dosing frequency of interferon beta-1a. Its products under Phase III clinical trials consist of Daclizumab, a monoclonal antibody in relapsing MS; TYSABRI for secondary progressive MS; and GA101, a monoclonal antibody for chronic lymphocytic leukemia and NHL. The company’s Phase II clinical trial products include Anti-LINGO for optic neuritis; STX-100 for idiopathic pulmonary fibrosis; Neublastin for neuropathic pain; and ANTI-TWAEK for lupus nephritis. Its Phase I clinical trial products comprise BIIB037 for Alzheimer's disease; BIIB037 for MS; and Anti-CD40 Ligand for general lupus, as well as Phase 1b/2a clinical trial products include ISIS-SMNRx for spinal muscular atrophy. Biogen Idec Inc. has collaboration agreements with Genentech, Inc.; Acorda Therapeutics, Inc.; Sangamo BioSciences; and Swedish Orphan Biovitrum AB. The company was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec Inc. in November 2003. Biogen Idec Inc. was founded in 1985 and is headquartered in Cambridge, Massachusetts.

6,850 Employees
Last Reported Date: 02/6/14
Founded in 1985

biogen idec inc (IDP) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $1.5M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $745.2K
Executive Vice President of Global Commercial...
Total Annual Compensation: $675.1K
Executive Vice President of Research & Develo...
Total Annual Compensation: $766.8K
Executive Vice President of Pharmaceutical Op...
Total Annual Compensation: $625.6K
Compensation as of Fiscal Year 2013.

biogen idec inc (IDP) Key Developments

Biogen Idec Announces European Commission Grants Marketing Authorization for PLEGRIDY(TM) (peginterferon beta-1a) as Treatment for Adults with Relapsing-Remitting Multiple Sclerosis

Biogen Idec announced that the European Commission (EC) has granted marketing authorization for PLEGRIDY(TM) (peginterferon beta-1a) as a treatment for adults with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). PLEGRIDY is dosed once every two weeks and is administered subcutaneously with the PLEGRIDY PEN, a new ready-to-use autoinjector, or a prefilled syringe. PLEGRIDY, the only pegylated interferon approved for use in RRMS, has been proven to significantly reduce important measures of disease activity, including number of relapses, MRI brain lesions, and disability progression. The EC approval of PLEGRIDY is based on results from one of the pivotal studies of a beta interferon conducted, ADVANCE, which involved more than 1,500 patients with relapsing forms of MS. In the ADVANCE clinical trial, PLEGRIDY, dosed once every two weeks, significantly reduced annualized relapse rate (ARR) at one year by 36% compared to placebo (p=0.0007). PLEGRIDY reduced the risk of sustained disability progression confirmed at twelve weeks by 38% (p=0.0383) and at twenty four weeks by 54% (p=0.0069, post-hoc analysis). In addition, the number of gadolinium-enhancing [Gd+] lesions was significantly reduced by 86% (p<0.0001) compared to placebo. Results over two years of ADVANCE confirm that its robust efficacy was maintained beyond the placebo-controlled first year of the study.

Biogen Idec Inc. Announces Unaudited Consolidated Financial Results for the Second Quarter and Six Months Ended June 30, 2014; Revised Earnings Guidance for the Year of 2014

Biogen Idec Inc. announced unaudited consolidated financial results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenues of $2,421,452,000 against $1,723,473,000 a year ago. Income from operations was $988.725 million against $662.527 million a year ago. Income before income tax expense and equity in loss of investee, net of tax was $993.586 million against $652.099 million a year ago. Net income attributable to the company was $714.506 million or $3.01 per diluted share against $490.670 million or $2.06 per diluted share a year ago. Non-GAAP earnings per diluted share was $3.49 million against $2.30 million a year ago. Non-GAAP net income attributable to the company was $829.1 million against $548.8 million a year ago. For the six months, the company reported total revenues of $4,551,203,000 against $3,138,569,000 a year ago. Income from operations was $1,660.073 million against $1,173.052 million a year ago. Income before income tax expense and equity in loss of investee, net of tax was $1,659.333 million against $1,148.167 million a year ago. Net income attributable to the company was $1,194.462 million or $5.03 per diluted share against $917.419 million or $3.85 per diluted share a year ago. Non-GAAP earnings per diluted share was $5.96 million against $4.27 million a year ago. Non-GAAP net income attributable to the company was $1,415.9 million against $1,018.2 million a year ago. The company increased its full year 2014 financial guidance. This change represents a meaningful increase from prior guidance owing primarily to the growth of TECFIDERA in the U.S. and the E.U., the strength of other MS therapies, and clarity on the AIFA pricing matter. For the year of 2014, the company's projected GAAP net income attributable to company of $2,697 million or $11.36 per diluted share. Amortization of acquired intangible assets of $463 million. Projected Non-GAAP net income attributable to company is $3,085 million or $13.00 per diluted share.

Biogen Idec Seeks Acquisitions

Biogen Idec Inc. (NasdaqGS:BIIB) will seek acquisitions. Paul Clancy, Executive Vice President and Chief Financial Officer of Biogen Idec said, "Our strategic bias is, remains these tuck-in acquisitions where we think it's core of the business and great internal rates of return and all that."

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IDP:GR €245.85 EUR -5.52

IDP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AbbVie Inc $52.09 USD -0.255
Bristol-Myers Squibb Co $50.16 USD -0.46
Celgene Corp $87.05 USD -0.10
Novo Nordisk A/S kr251.20 DKK -6.70
Shire PLC 4,871 GBp -20.00
View Industry Companies
 

Industry Analysis

IDP

Industry Average

Valuation IDP Industry Range
Price/Earnings 37.2x
Price/Sales 9.5x
Price/Book 8.3x
Price/Cash Flow 30.7x
TEV/Sales 9.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BIOGEN IDEC INC, please visit www.biogenidec.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.